Detalles de la búsqueda
1.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(2): 234-247, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35030335
2.
Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.
Int J Clin Oncol
; 26(12): 2205-2215, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34586548
3.
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Gastroenterol Hepatol
; 2024 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38906161
4.
A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
J Dermatol Sci
; 103(3): 135-142, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34376340
Resultados
1 -
4
de 4
1
Próxima >
>>